HOUSE_OVERSIGHT_024043.jpg
2.73 MB
Extraction Summary
0
People
11
Organizations
0
Locations
0
Events
2
Relationships
2
Quotes
Document Information
Type:
Investment memorandum / prospectus (page 32)
File Size:
2.73 MB
Summary
This document is page 32 of a confidential investment memorandum (Control Number 257) produced for the House Oversight Committee. It outlines the investment strategy for 'NLV-III' (New Leaf Ventures III), focusing on biopharmaceutical companies with novel products or platforms. The text highlights past successes of the fund managers, listing exit multiples for companies such as Array BioPharma, Pearl Therapeutics, and Epizyme.
Organizations (11)
| Name | Type | Context |
|---|---|---|
| NLV-III |
The fund described in the document targeting biopharmaceutical investments.
|
|
| NLV-II |
Previous fund cited for portfolio examples.
|
|
| NLV-I |
Previous fund cited for portfolio examples.
|
|
| Array BioPharma |
Cited as a successful oncology investment in NLV-II.
|
|
| Chimerix |
Cited as a viral therapy investment in NLV-II.
|
|
| Versartis |
Cited as a growth hormone investment in NLV-II.
|
|
| Pearl Therapeutics |
Cited as a pulmonology investment in NLV-I.
|
|
| Epizyme |
Cited as an oncology investment in NLV-II.
|
|
| Principia |
Cited as an immunology & oncology investment in NLV-II.
|
|
| NASDAQ |
Mentioned regarding the listing status of portfolio companies.
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT'.
|
Relationships (2)
Examples of these types of biopharmaceutical investments in the NLV portfolio are Array BioPharma (NLV-II...)
Pearl Therapeutics (NLV-I, private, pulmonology, exited at 2.5x plus milestones)
Key Quotes (2)
"Investments in the biopharmaceutical sector within NLV-III will target companies that are developing products that address clinically important unmet medical needs with competitively differentiated technologies."Source
HOUSE_OVERSIGHT_024043.jpg
Quote #1
"The Fund Managers expect to identify investment opportunities within private or public companies whose primary asset(s) fall within one of the following categories"Source
HOUSE_OVERSIGHT_024043.jpg
Quote #2
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document